GEN Exclusives

More »

Tech Notes

More »
Sep 15, 2009 (Vol. 29, No. 16)

Parvovirus B19 VLP Vaccine Manufacturing

Meridian Developed Production Process for Technology Licensed from NHLBI

  • Conclusions

    Multiple groups are at risk of potentially life-threatening complications due to human parvovirus B19 infection. Based on the infectious nature of HPVB19 infection in children and the severe potential consequence of transplacental fetal infection, a two-pronged vaccination strategy to manage HPVB19 infections in these populations is recommended.

    First, incorporation of a HPVB19 vaccine into the early childhood vaccination schedule could reduce the overall incidence of this virus in the population. Second, a safe vaccine that can elicit protective neutralizing antibodies could be provided to women of childbearing age as prophylactic care to reduce the overall incidence of transplacental fetal infection.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?